Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose tacrolimus plus hormone versus hormone alone for idiopathic FSGS
ChiCTR2000031003Phase 4Recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Dec 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus in focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: 24-hour urine protein quantification. Started Dec 2019; status: recruiting.
02
Drugs
tacrolimus
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on ChiCTR2000031003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031003.